Compounds > estra-1(10),4-diene-2,3,17-trione
Page last updated: 2024-11-07
estra-1(10),4-diene-2,3,17-trione
Description
estra-1(10),4-diene-2,3,17-trione: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
estra-1(10),4-diene-2,3,17-trione : An o-quinone resulting from the formal oxidation of the dihydroxyphenyl moiety of 2-hydroxyestrone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 148381 |
| CHEBI ID | 87262 |
| MeSH ID | M0230065 |
Synonyms (12)
| Synonym |
|---|
| 2,3-estrone o-quinone |
| (8r,9s,13s,14s)-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-2,3,17-trione |
| e1-2,3-q |
| estra-1(10),4-diene-2,3,17-trione |
| estrone-2,3-quinone |
| 2,3-estrone ortho-quinone |
| 2,3-eq |
| 40551-33-5 |
| 2,3-estrogen o-quinone |
| CHEBI:87262 |
| Q20742851 |
| DTXSID70960965 |
Roles (1)
| Role | Description |
|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| 3-oxo-Delta(4) steroid | A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position. |
| 17-oxo steroid | Any oxo steroid carrying the oxo group at position 17. |
| orthoquinones | Any quinone in which the carbons of the two carbonyl groups in the quinone system are joined to each other by a single bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (3)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.74
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.74 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.54 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |